News Channels

09 May 2017 OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
09 May 2017 NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
09 May 2017 Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
09 May 2017 FDA Grants Second Approval for BAVENCIO® (avelumab)
09 May 2017 AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease
09 May 2017 FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
09 May 2017 Addex ADX71441 Demonstrates Preclinical Analgesic Effects
09 May 2017 Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
09 May 2017 Exscientia Announces EUR250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi
09 May 2017 Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics
09 May 2017 PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections
09 May 2017 Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies
09 May 2017 OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
09 May 2017 VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies
08 May 2017 CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
08 May 2017 Crown Bioscience Announces Collaboration to Develop Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Antibody
08 May 2017 Tau Immunotherapy Shows Great Potential in Pre-Clinical Studies
08 May 2017 Embera NeuroTherapeutics Announces Positive Topline Data from Phase 1b Cocaine Interaction Study of EMB-001
08 May 2017 Rasna Therapeutics, Inc. Advances Development of a Novel Treatment for NPM1-mutated Acute Myeloid Leukemia
08 May 2017 Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing